11:38 AM EST, 12/19/2024 (MT Newswires) -- Immix Biopharma ( IMMX ) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.

All four patients normalized their disease markers within 30 days of treatment, with two achieving a complete response, while the other two showed minimal residual disease negativity in the bone marrow.

The treatment demonstrated good tolerability, with no neurotoxicity, severe cytokine-release syndrome, febrile neutropenia, treatment-related infections, cardiac toxicity, or deaths, the biopharmaceutical company said.

Immix Biopharma ( IMMX ) said it intends to proceed with enrollment, expecting interim data in Q2 or Q3 2025 and final topline results by Q2 or Q3 2026.

Shares of Immix Biopharma ( IMMX ) were up 2.8% in recent Thursday trading.

Price: 2.21, Change: +0.11, Percent Change: +5.33